Ivermectin and Kidney Function: Is There a Risk? What the 2026 Evidence Actually Shows
As ivermectin use has expanded dramatically — from its established role in FDA-approved antiparasitic treatment to off-label cancer adjunct protocols, COVID-19 research, and anti-ageing investigations — one question is increasingly asked by patients and clinicians: does ivermectin carry a risk to kidney function, and is it safe for the millions of Americans with chronic kidney disease (CKD)?
The honest answer in 2026 is nuanced. The good news is that ivermectin is primarily eliminated by the liver and feces — less than 1% of unchanged ivermectin is excreted in urine — which means the kidneys are not the primary organ of elimination. This makes ivermectin fundamentally different from drugs like gabapentin (which are entirely renally cleared) where kidney disease directly causes dangerous drug accumulation. For most patients with mild to moderate CKD taking ivermectin at standard therapeutic doses for approved antiparasitic indications, routine dose adjustment is generally not required per current clinical guidance.
However, the full picture is more complicated. Animal studies — including a 2025 Fırat University study and a NIH PMC-indexed Brazilian study — show that ivermectin at high doses causes measurable oxidative stress and kidney function impairment in animal models, particularly in animals with pre-existing renal vulnerability. A 2026 Factually evidence review identified rare but documented human cases of severe glomerulonephritis temporally linked to ivermectin. And clinical commentators consistently flag that elderly patients, patients with advanced CKD, and patients taking high or repeated off-label doses represent under-studied, higher-risk populations.
This complete 2026 guide provides the most accurate, evidence-based answer to the kidney question — covering how ivermectin is processed by the body (why the liver-first elimination is largely protective), what the animal study evidence actually shows and why dose context matters, the rare but real human adverse event reports, who is at highest risk and why, specific monitoring recommendations, and the practical guidance for patients with CKD considering ivermectin.
MedlinePlus provides comprehensive ivermectin patient information at: https://medlineplus.gov/druginfo/meds/a607069.html
How Ivermectin Is Processed — Why Kidney Excretion Is Minimal
The starting point for understanding ivermectin's kidney risk is its pharmacokinetic profile — specifically, how it enters the body, where it goes, and how it leaves:
Absorption:
Ivermectin is absorbed from the gastrointestinal tract into the bloodstream. Absorption is significantly improved when taken with a fatty meal — fat increases bioavailability, which is why high-fat food co-administration is sometimes recommended in protocols seeking maximum systemic exposure. On an empty stomach, bioavailability is substantially lower.
Distribution:
After absorption, ivermectin is highly protein-bound (approximately 93% bound to plasma proteins). It distributes into body tissues, particularly fat and liver tissue. It crosses the blood-brain barrier poorly in most adults (protected by P-glycoprotein efflux transporters) — which explains its selective safety in humans versus the CNS toxicity it causes in parasites that lack these transporters.
Metabolism — primarily hepatic:
Ivermectin is extensively metabolised in the liver by cytochrome P450 enzymes (primarily CYP3A4). The liver converts ivermectin into multiple metabolites, the majority of which are eliminated in the feces via bile. This hepatic-biliary elimination is the dominant clearance pathway.
Renal excretion — less than 1%:
Less than 1% of administered ivermectin is excreted unchanged in urine. This is the pharmacokinetic basis for the standard clinical guidance that "ivermectin does not require dose adjustment for mild-to-moderate renal impairment" — because so little of the drug passes through the kidneys as unchanged compound, kidney dysfunction does not cause significant drug accumulation in the way that it does for renally-cleared drugs.
The important implication:
This pharmacokinetic profile means that ivermectin, at therapeutic doses for standard antiparasitic indications, does not place the kidneys under the same direct burden that renally-excreted drugs do. The kidney is not a primary elimination organ for ivermectin — it is a secondary target of potential off-target toxicity through oxidative stress mechanisms, not through direct drug accumulation.
What the Animal Studies Show — The Oxidative Stress Mechanism
Despite the reassuring pharmacokinetics, a consistent body of animal evidence has identified nephrotoxic effects of ivermectin under specific conditions. Understanding these studies — their doses, their designs, and their limitations — is essential for interpreting the risk accurately:
Brazilian ischemia-reperfusion study (published in REBEN — Brazilian Nursing Journal):
This study divided adult male Wistar rats into four groups: sham surgery (control), renal ischemia alone, sham + ivermectin (10mg/kg daily for 5 days), and ischemia + ivermectin. Key findings:
Ivermectin caused a decrease in creatinine clearance even in animals without pre-existing ischemia
In animals with pre-existing renal ischemia, ivermectin significantly worsened renal function parameters and increased oxidative stress markers
The proposed mechanism: osmotic nephrosis — a form of kidney injury where cells take up excessive fluid and swell
Conclusion: "Ivermectin demonstrated nephrotoxic activity based on the mechanism of osmotic nephrosis, and showed additional worsening of renal function parameters and oxidative stress when associated with previous renal injury"
NIH PMC oxidative stress study (Wistar rats, indexed PMC8693136):
This study administered 4 doses of ivermectin at 0.4mg/kg to rats with and without concurrent Vitamin C:
Ivermectin alone caused attenuation in kidney function markers
Increased matrix metalloproteinase-9 (MMP-9) activity — an enzyme involved in tissue remodelling and injury
Reduced antioxidant enzyme activity (superoxide dismutase, catalase, glutathione peroxidase)
Vitamin C co-administration provided partial protection against these effects
The proposed pathway: ivermectin-induced oxidative stress → free radical accumulation → direct renal tubular cell damage
Fırat University 2025 study (Fırat University Journal of Health Sciences):
This 2025 study specifically investigated the protective role of folic acid against ivermectin-induced renal toxicity. Key findings:
Ivermectin increased biomarkers of kidney toxicity, apoptosis, and lipid peroxidation
Increased NF-κB, TNF-α, caspase-3, Bax, and kidney injury molecule-1 (KIM-1) — all markers of renal inflammation and cell death
Decreased antioxidant enzyme activity and aquaporin-2 (important for renal water transport)
Folic acid supplementation significantly protected against these effects
Critical context — the dose gap:
The doses used in most animal nephrotoxicity studies are substantially higher than standard human therapeutic doses. Rat studies often use 0.4–15mg/kg — at the high end, this far exceeds the human therapeutic range of 0.15–0.4mg/kg for most indications. Extrapolating animal toxicity data to human clinical practice requires careful dose-adjustment thinking. A dose that is nephrotoxic in a rat study at 10mg/kg is not directly comparable to a human taking a single 12mg dose for scabies. However, the mechanistic plausibility these studies establish — that oxidative stress-mediated renal injury is biologically possible with ivermectin — remains scientifically relevant, particularly for high-dose or repeated-dose scenarios.
What the Human Evidence Shows — Limited but Important
Human clinical evidence on ivermectin and kidney function is substantially more limited than the animal data:
Standard therapeutic dose clinical trials — reassuring:
Large-scale clinical trials of ivermectin for onchocerciasis (river blindness) and lymphatic filariasis mass drug administration programmes have administered ivermectin to hundreds of thousands of patients globally, with renal adverse events not appearing as a significant signal in these programmes. This broad real-world safety experience at standard antiparasitic doses is the strongest evidence for relative renal safety under normal use conditions.
The Mazzotti reaction — transient proteinuria:
When ivermectin kills large numbers of microfilariae (parasite larvae) rapidly, the immune response to dying parasite antigens can cause a Mazzotti reaction — which may include transient proteinuria (protein in the urine). This is not direct kidney damage but rather an inflammatory response to parasite die-off that typically resolves as the reaction subsides.
Human adverse event reports — rare but documented:
A January 29, 2026 Factually evidence review identified a single well-documented case of severe glomerulonephritis (kidney inflammation) temporally linked to ivermectin use, along with a small number of pharmacovigilance reports of renal events in ivermectin users. The review concluded: "Robust human evidence that ivermectin commonly causes AKI at therapeutic doses is lacking — the only strong human adverse-event report is a single case abstract of severe glomerulonephritis temporally linked to ivermectin."
High and repeated off-label dose risk — the under-studied population:
A January 5, 2026 Factually review specifically flagged: "Never assume safety when people take high or repeated off-label doses (common in informal COVID-era self-medication reports) — the animal toxicology and case reports argue for dose prudence and for monitoring urine and renal function when there is clinical concern."
This is the critical 2026-specific safety message: the safety profile established in regulated antiparasitic clinical trials may not apply to:
High-dose ivermectin (significantly exceeding 0.4mg/kg per dose)
Repeated frequent dosing schedules (daily or every-other-day dosing in some cancer protocols)
Self-medication without monitoring or medical supervision
Patients with pre-existing CKD who were not well-represented in the original clinical trial populations
Who Is at Highest Kidney Risk — Risk Stratification
Based on the combined 2026 evidence, the following patient populations warrant particular attention regarding ivermectin and renal function:
Risk Category | Patients | Recommended Approach |
Standard risk — normal renal function | Healthy adults taking standard antiparasitic doses (0.15–0.4 mg/kg single dose) | No specific renal monitoring required; standard clinical follow-up |
Caution — mild to moderate CKD (eGFR 30–60) | Adults with Stage 2–3 CKD; stable; not on dialysis | No dose adjustment generally required for single-dose antiparasitic use; clinical judgment for repeated dosing; periodic creatinine monitoring reasonable |
Higher caution — advanced CKD (eGFR below 30) | Stage 4–5 CKD; pre-dialysis | Under-represented in trials; use lowest effective dose; renal function monitoring before and after treatment; consider specialist input |
Dialysis patients | On haemodialysis or peritoneal dialysis | Very limited data; consult nephrologist; standard elimination pathway (hepatic-biliary) should be largely preserved but toxicity metabolites may accumulate |
Highest risk — high or repeated off-label doses | Cancer adjunct protocols, anti-ageing use, high-dose COVID protocols | Establish baseline creatinine and eGFR; monitor at 2–4 weeks during any prolonged course; watch for symptoms of renal injury; do not exceed 0.4mg/kg per dose without specialist oversight |
Pre-existing acute kidney injury (AKI) | Active AKI from any cause | Avoid ivermectin until renal function has stabilised — animal evidence specifically shows worsening of function in ischemic/injured kidneys |
Elderly patients (age 70+) | Reduced renal reserve; polypharmacy; potentially reduced P-glycoprotein function | Start conservatively; monitor renal function; avoid concurrent nephrotoxic drugs |
Symptoms That Could Indicate Kidney Stress on Ivermectin
Patients on ivermectin — particularly at higher doses or with extended use — should be aware of these potential warning signs of renal involvement:
Reduced urine output or very concentrated dark urine
Swelling of the ankles, feet, or face (oedema from impaired fluid regulation)
Foamy or frothy urine (may indicate proteinuria — protein in the urine)
Flank or lower back pain (kidney area discomfort)
Unusual fatigue, nausea, or loss of appetite (systemic signs of compromised renal function)
Elevated blood pressure developing or worsening
These symptoms are non-specific and can have many causes. However, any patient on ivermectin — particularly at high doses or with pre-existing CKD — experiencing these symptoms should have renal function assessed promptly (blood creatinine, eGFR, urinalysis).
Monitoring Recommendations — Practical 2026 Guidance
For standard antiparasitic use (single dose, normal renal function):
No specific kidney monitoring is required. A clinical review at follow-up to confirm treatment efficacy is standard practice.
For patients with mild-moderate CKD (eGFR 30–60) using standard antiparasitic doses:
Baseline creatinine and eGFR before treatment
Clinical review 2–4 weeks post-treatment
Urinalysis to check for proteinuria if symptomatic
For patients on extended or high-dose protocols (cancer adjunct, off-label):
Establish baseline creatinine, eGFR, and urinalysis before starting
Monitor at 4-week intervals during any prolonged course
Stop and reassess if creatinine rises more than 20–30% from baseline
Avoid concurrent nephrotoxic drugs (NSAIDs, contrast agents, aminoglycosides)
Stay well hydrated — dehydration concentrates ivermectin metabolites in renal tubules
Potential protective measures (emerging evidence):
Adequate hydration throughout treatment
Vitamin C: the NIH PMC rat study showed partial protection; reasonable to maintain adequate dietary vitamin C
Folic acid: the 2025 Fırat University study showed folic acid protected against ivermectin-induced renal biomarkers in animals; a reasonable adjunct at standard supplementation doses, though human evidence is not yet established
Avoid combining ivermectin with other potentially nephrotoxic agents during intensive protocols
The Balanced Honest Assessment — 2026
The most accurate answer to "is there a kidney risk with ivermectin?" is:
At standard therapeutic doses for FDA-approved antiparasitic indications in adults with normal or mildly impaired kidney function: the risk is low. The pharmacokinetic profile (less than 1% renal excretion) and the extensive real-world antiparasitic safety record both support this conclusion. Routine kidney monitoring for a standard scabies or strongyloidiasis treatment course is not warranted for most patients.
For high-dose, frequent, or repeated off-label use (cancer protocols, anti-ageing, extended self-medication): the risk is uncertain but not negligible. Animal evidence consistently demonstrates dose-dependent oxidative stress and kidney function impairment. Human evidence is sparse but includes at least one case of severe glomerulonephritis. Patients in this category should not assume that the established safety profile for single-dose antiparasitic use applies to their situation. Monitoring is prudent.
For patients with pre-existing CKD, particularly advanced CKD or active AKI: clinical caution is appropriate. These patients were underrepresented in the clinical trial populations that established ivermectin's safety profile, and the animal evidence specifically shows worse outcomes when ivermectin is given to kidneys that are already compromised.
For our complete guide on chronic kidney disease — understanding eGFR stages, how drugs are adjusted for CKD, and why some drugs safe for healthy patients require monitoring in CKD: [Chronic Kidney Disease: Symptoms, Stages and Treatment Guide]
For our guide on oral ivermectin — FDA-approved uses, standard dosage, and the full antiparasitic evidence: [Ivermectin for Humans: FDA-Approved Uses, Strengths and Dosage Guide]
For our guide on ivermectin and cancer research — the 2026 clinical trial landscape and the off-label use context where monitoring matters most: [Ivermectin and Fenbendazole for Cancer: What the 2026 Science Actually Shows]
The NIH PMC-indexed study on ivermectin's effects on kidney function and oxidative stress in rats is available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8693136/
TheMedicineKart stocks FDA-comparable ivermectin tablets in multiple strengths for patients with valid prescriptions: [Ivermectin 12mg Tablets]
Frequently Asked Questions
Is ivermectin safe for people with chronic kidney disease?
For most patients with mild to moderate CKD (eGFR above 30 mL/min), ivermectin at standard antiparasitic doses is generally considered safe without dose adjustment — because less than 1 percent of ivermectin is excreted unchanged in urine, and the drug is primarily eliminated by the liver and bile. However, patients with advanced CKD (eGFR below 30) or active acute kidney injury were underrepresented in the clinical trials that established this safety profile. For these patients, clinical caution and renal function monitoring are appropriate. Always inform your prescriber of any kidney disease before starting ivermectin.
Can ivermectin damage the kidneys?
Animal studies show that ivermectin at high doses causes oxidative stress and measurable kidney function impairment in rats — particularly when the kidney is already injured. Human evidence for kidney damage at standard therapeutic doses is limited to rare case reports, with one documented case of severe glomerulonephritis temporally linked to ivermectin. At standard antiparasitic doses in patients with normal kidney function, robust human evidence for common kidney damage is lacking. The risk appears to increase significantly with high or repeated off-label doses and in patients with pre-existing kidney vulnerability.
Does ivermectin need a dose reduction in kidney disease?
For mild to moderate CKD, standard clinical guidance does not require ivermectin dose adjustment, because the drug is not primarily renally cleared. This is different from drugs like gabapentin or metformin, which require significant dose adjustment in CKD because they accumulate due to reduced renal excretion. However, for patients with severe CKD (Stage 4–5) or active AKI, the evidence base is insufficient to confirm safety, and specialist input is advisable before any extended ivermectin use.
What are the warning signs of kidney problems while taking ivermectin?
Warning signs that may indicate renal involvement include: reduced or unusually concentrated urine output, swelling of the ankles or feet, foamy or frothy urine (possible proteinuria), flank or lower back discomfort, unusual fatigue, nausea, or loss of appetite. These signs are non-specific and have many causes, but patients on high-dose or extended ivermectin protocols with any of these symptoms should have blood creatinine, eGFR, and urinalysis checked promptly.
Is there anything that can protect the kidneys while taking ivermectin?
Emerging animal evidence suggests that vitamin C and folic acid may offer partial protection against ivermectin-induced oxidative kidney stress — the NIH PMC rat study showed vitamin C reduced kidney injury markers, and a 2025 Fırat University study demonstrated folic acid significantly protected against ivermectin-induced nephrotoxicity biomarkers. While these findings have not been confirmed in human clinical trials, maintaining adequate hydration, avoiding concurrent nephrotoxic drugs (NSAIDs, contrast dyes), and ensuring dietary adequacy of antioxidant vitamins represent reasonable practical steps. For prolonged or high-dose protocols, regular monitoring of renal function is the most evidence-supported protective measure.
Comments